157 related articles for article (PubMed ID: 33041228)
1. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2020 Oct; ():. PubMed ID: 33041228
[TBL] [Abstract][Full Text] [Related]
2. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.
Tornero-Molina J; Alperi-López M; Castellví I; de Agustín-de Oro JJ; Escudero A; García-Vicuña R; González-Gay MÁ; Hidalgo C; Rubio E; Sanmartí R; Casamira N; Calvo-Alén J
Reumatol Clin (Engl Ed); 2022 Jan; 18(1):33-41. PubMed ID: 35090610
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the use of methotrexate in psoriatic arthritis.
Cañete JD; Ariza-Ariza R; Bustabad S; Delgado C; Fernández-Carballido C; García Llorente JF; Loza E; Montilla C; Naranjo A; Pinto JA; Queiro R; Ramírez J; Tornero-Molina J
Reumatol Clin (Engl Ed); 2018; 14(4):183-190. PubMed ID: 29050840
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the use of parenteral methotrexate in rheumatic diseases.
Tornero Molina J; Calvo Alen J; Ballina J; Belmonte MÁ; Blanco FJ; Caracuel MÁ; Carbonell J; Corominas H; Chamizo E; Hidalgo C; Ivorra JR; Marenco JL; Moreno Muelas JV; Muñoz-Fernández S; Nolla JM; Pérez T; Sanmarti R; Trenor P; Urrego C; Vidal J; Rosas Gomez de Salazar J
Reumatol Clin (Engl Ed); 2018; 14(3):142-149. PubMed ID: 28082032
[TBL] [Abstract][Full Text] [Related]
5. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.
Tornero Molina J; Balsa Criado A; Blanco García F; Blanco Alonso R; Bustabad S; Calvo Alen J; Corominas H; Fernández Nebro A; Román Ivorra JA; Sanmartí R
Reumatol Clin (Engl Ed); 2020; 16(4):272-281. PubMed ID: 30098882
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.
Calvo Alén J; Pérez T; Romero Yuste S; Ferraz-Amaro I; Alegre Sancho JJ; Pinto Tasende JA; Maceiras Pan F; Quevedo JC; Hernández-Hernández MV; Hidalgo Calleja C; San Martín Álvarez A; Sánchez MIT; Sanmartí R
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):324-332. PubMed ID: 30241955
[TBL] [Abstract][Full Text] [Related]
7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
[TBL] [Abstract][Full Text] [Related]
10. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
11. 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs.
Momen Majumder MS; Hasan ATMT; Choudhury MR; Ahmed S; Miah MT; Amin MR; Shahin MA; Islam A; Shazzad MN; Hassan MM; Ahmedullah AK; Rahman MM; Yesmeen S; Uddin T; Haq SA
Cureus; 2024 Apr; 16(4):e59395. PubMed ID: 38707172
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
[TBL] [Abstract][Full Text] [Related]
13. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.
Sanmartí R; García-Rodríguez S; Álvaro-Gracia JM; Andreu JL; Balsa A; Cáliz R; Fernández-Nebro A; Ferraz-Amaro I; Gómez-Reino JJ; González-Álvaro I; Martín-Mola E; Martínez-Taboada VM; Ortiz AM; Tornero J; Marsal S; Moreno-Muelas JV
Reumatol Clin; 2015; 11(5):279-94. PubMed ID: 26051464
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
17. [Portuguese recommendations for the use of methotrexate in the treatment of rheumatoid arthritis].
Canhão H; Santos MJ; Costa L; Bogas M; Mourão AF; Machado P; Fonseca JE; Silva JA;
Acta Reumatol Port; 2009; 34(1):78-95. PubMed ID: 19377402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
